DNA fingerprinting of the NCI-60 cell line panel

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 713-724

  Lorenzi, Philip L ^a   Reinhold, William C ^a   Varma, Sudhir ^a,d   Hutchinson, Amy A ^a,b   Pommier, Yves ^a   Chanock, Stephen J ^a   Weinstein, John N ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MINISATELLITE; DNA; MICROSATELLITE DNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM; DNA FINGERPRINTING; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; MELANOMA CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SHORT TANDEM REPEAT; CLASSIFICATION; GENETICS; NATIONAL HEALTH ORGANIZATION; NEOPLASM; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UNITED STATES;

CELL LINE, TUMOR; DNA FINGERPRINTING; DNA, NEOPLASM; HUMANS; MICROSATELLITE REPEATS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 66449108540     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0921     Document Type: Article

References (31)

1. Robinson LB, Wichelhausen RH. Contamination of human cell cultures by pleuropneumonia like organisms. Science 1956;124:1147-1148, PubMed doi:10.1126/science.124.3232.1147.
2. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999;83:555-63, PubMed doi: 10.1002/(SICI)1097- 0215(19991112)83:4〈555::AID-IJC19〉3.0.CO;2-2. (Pubitemid 29489873)
3. Masters J. Re: false cell lines. Exp Cell Res 2002;272:216, PubMed doi:10.1006/excr.2001.5439.
4. Nelson-Rees WA, Flandermeyer RR, Hawthorne PK. Banded marker chromosomes as indicators of intraspecies cellular contamination. Science 1974;184:1093-1096, PubMed doi:10.1126/science.184.4141.1093.
5. Nelson-Rees WA, Zhdanov VM, Hawthorne PK, Flandermeyer RR. HeLa-like marker chromosomes and type-A variant glucose-6-phosphate dehydrogenase isoenzyme in human cell cultures producing Mason-Pfizer monkey virus-like particles. J Natl Cancer Inst 1974;53:751-757, PubMed.
6. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109, doi:10.1002/ddr.430340203.
7. Holbeck SL. Update on NCI in vitro drug screen utilities. Eur J Cancer 2004;40:785-793, PubMed doi:10.1016/j.ejca.2003.11.022. (Pubitemid 38519757)
8. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-823, PubMed doi:10.1038/nrc1951. (Pubitemid 44450469)
9. Weinstein JN. Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 2006;5:2601-5, PubMed doi:10.1158/1535-7163.MCT-06-0640.
10. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008;7:1-9, PubMed doi:10.1158/1535-7163.MCT-07-0573.
11. Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007;6:1483-91, PubMed doi:10.1158/1535-7163.MCT-07-0009. (Pubitemid 46954015)
12. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12, PubMed doi:10.1158/1535-7163.MCT-06-0433. (Pubitemid 44848987)
13. Ikediobi ON, Reimers M, Durinck S, et al. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol Cancer Ther 2008;7:1337-46, PubMed doi: 10.1158/1535-7163. MCT-07-2308.
14. Lorenzi PL, Llamas J, Gunsior M, et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008;7:3123-3128 (Pubitemid 44848988)
15. Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006;5:2613-23, PubMed doi:10.1158/1535- 7163.MCT-06-0447. (Pubitemid 44848988)
16. Reinhold WC, Reimers MA, Maunakea AK, et al. Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 2007;6:391-403, PubMed doi:10.1158/1535-7163.MCT- 06-0609. (Pubitemid 46332442)
17. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32, PubMed doi: 10.1158/1535-7163.MCT-06-0650. (Pubitemid 46554552)
18. Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008;7:10-8, PubMed doi:10.1158/1535-7163.MCT-07-0192.
19. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-8647, PubMed. (Pubitemid 38064038)
20. Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67, PubMed doi: 10.1158/1535-7163.MCT-05-0155. (Pubitemid 43724584)
21. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-235, PubMed doi:10.1038/73432. (Pubitemid 30132189)
22. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-244, PubMed doi:10.1038/73439. (Pubitemid 30132190)
23. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-122, PubMed doi:10.1038/nature 03664. (Pubitemid 40966196)
24. Jeffreys AJ, Wilson V, Thein SL. Individual-specific 'fingerprints' of human DNA. Nature 1985;316:76-79, PubMed doi:10.1038/316076a0.
25. Butler JM. Genetics and genomics of core short tandem repeat loci used in human identity testing. J Forensic Sci 2006;51:253-265, PubMed doi:10.1111/j.1556-4029.2006.00046.x.
26. Oldroyd NJ, Urquhart AJ, Kimpton CP, et al. A highly discriminating octoplex short tandem repeat polymerase chain reaction system suitable for human individual identification. Electrophoresis 1995;16:334-337, PubMed doi:10.1002/elps.1150160155.
27. Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001;98:8012-8017, PubMed doi:10.1073/ pnas.121616198. (Pubitemid 32642678)
28. Stinson SF, Alley MC, Kopp WC, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992;12:1035-1053, PubMed.
29. Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001;61:1964-1969, PubMed. (Pubitemid 32692014)
30. Santos FR, Pandya A, Tyler-Smith C. Reliability of DNA-based sex tests. Nat Genet 1998;18:103, PubMed doi:10.1038/ng0298-103.
31. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-2330, PubMed doi:10.1038/sj.onc.1203598. (Pubitemid 30307208)